

Chronic Idiopathic Constipation Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/CA3C574A3B0MEN.html>

Date: May 2018

Pages: 146

Price: US\$ 3,480.00 (Single User License)

ID: CA3C574A3B0MEN

Abstracts

Report Summary

Chronic Idiopathic Constipation Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Chronic Idiopathic Constipation Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Chronic Idiopathic Constipation Drugs 2013-2017, and development forecast 2018-2023

Main market players of Chronic Idiopathic Constipation Drugs in EMEA, with company and product introduction, position in the Chronic Idiopathic Constipation Drugs market
Market status and development trend of Chronic Idiopathic Constipation Drugs by types and applications

Cost and profit status of Chronic Idiopathic Constipation Drugs, and marketing status
Market growth drivers and challenges

The report segments the EMEA Chronic Idiopathic Constipation Drugs market as:

EMEA Chronic Idiopathic Constipation Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Chronic Idiopathic Constipation Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Linaclootide

Lubiprostone

Other

EMEA Chronic Idiopathic Constipation Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

EMEA Chronic Idiopathic Constipation Drugs Market: Players Segment Analysis (Company and Product introduction, Chronic Idiopathic Constipation Drugs Sales Volume, Revenue, Price and Gross Margin):

Pfizer

Glaxosmithkline

Roche Holding AG

Sanofi

Bayer AG

Merck

Eli Lilly

Allergens

Chugai Pharmaceutical

Ferring International Center S.A

Synergy Pharmaceuticals

Salix Pharmaceuticals Ltd

Sucampo Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Valeant Pharmaceuticals International

Daiichi Sankyo

Cosmo Pharmaceuticals SA

Progenics Pharmaceuticals Inc

Theravance Biopharma Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS

- 1.1 Definition of Chronic Idiopathic Constipation Drugs in This Report
- 1.2 Commercial Types of Chronic Idiopathic Constipation Drugs
 - 1.2.1 Linaclotide
 - 1.2.2 Lubiprostone
 - 1.2.3 Other
- 1.3 Downstream Application of Chronic Idiopathic Constipation Drugs
 - 1.3.1 Hospital Pharmacies
 - 1.3.2 Retail Pharmacies
 - 1.3.3 Online Pharmacies
- 1.4 Development History of Chronic Idiopathic Constipation Drugs
- 1.5 Market Status and Trend of Chronic Idiopathic Constipation Drugs 2013-2023
 - 1.5.1 Asia Pacific Chronic Idiopathic Constipation Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Chronic Idiopathic Constipation Drugs Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Chronic Idiopathic Constipation Drugs in Asia Pacific 2013-2017
- 2.2 Consumption Market of Chronic Idiopathic Constipation Drugs in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Chronic Idiopathic Constipation Drugs in Asia Pacific by Regions
 - 2.2.2 Revenue of Chronic Idiopathic Constipation Drugs in Asia Pacific by Regions
- 2.3 Market Analysis of Chronic Idiopathic Constipation Drugs in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Chronic Idiopathic Constipation Drugs in China 2013-2017
 - 2.3.2 Market Analysis of Chronic Idiopathic Constipation Drugs in Japan 2013-2017
 - 2.3.3 Market Analysis of Chronic Idiopathic Constipation Drugs in Korea 2013-2017
 - 2.3.4 Market Analysis of Chronic Idiopathic Constipation Drugs in India 2013-2017
 - 2.3.5 Market Analysis of Chronic Idiopathic Constipation Drugs in Southeast Asia 2013-2017
 - 2.3.6 Market Analysis of Chronic Idiopathic Constipation Drugs in Australia 2013-2017
- 2.4 Market Development Forecast of Chronic Idiopathic Constipation Drugs in Asia Pacific 2018-2023
 - 2.4.1 Market Development Forecast of Chronic Idiopathic Constipation Drugs in Asia

Pacific 2018-2023

2.4.2 Market Development Forecast of Chronic Idiopathic Constipation Drugs by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Chronic Idiopathic Constipation Drugs in Asia Pacific by Types

3.1.2 Revenue of Chronic Idiopathic Constipation Drugs in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

3.3 Market Forecast of Chronic Idiopathic Constipation Drugs in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Chronic Idiopathic Constipation Drugs in Asia Pacific by Downstream Industry

4.2 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry in China

4.2.2 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry in Japan

4.2.3 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry in Korea

4.2.4 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry in India

4.2.5 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry in Southeast Asia

4.2.6 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry in Australia

4.3 Market Forecast of Chronic Idiopathic Constipation Drugs in Asia Pacific by

Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS

5.1 Asia Pacific Economy Situation and Trend Overview

5.2 Chronic Idiopathic Constipation Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 CHRONIC IDIOPATHIC CONSTIPATION DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

6.1 Sales Volume of Chronic Idiopathic Constipation Drugs in Asia Pacific by Major Players

6.2 Revenue of Chronic Idiopathic Constipation Drugs in Asia Pacific by Major Players

6.3 Basic Information of Chronic Idiopathic Constipation Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Chronic Idiopathic Constipation Drugs Major Players

6.3.2 Employees and Revenue Level of Chronic Idiopathic Constipation Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 CHRONIC IDIOPATHIC CONSTIPATION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Pfizer

7.1.1 Company profile

7.1.2 Representative Chronic Idiopathic Constipation Drugs Product

7.1.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Pfizer

7.2 Glaxosmithkline

7.2.1 Company profile

7.2.2 Representative Chronic Idiopathic Constipation Drugs Product

7.2.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Glaxosmithkline

7.3 Roche Holding AG

- 7.3.1 Company profile
- 7.3.2 Representative Chronic Idiopathic Constipation Drugs Product
- 7.3.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Roche Holding AG
- 7.4 Sanofi
 - 7.4.1 Company profile
 - 7.4.2 Representative Chronic Idiopathic Constipation Drugs Product
 - 7.4.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 7.5 Bayer AG
 - 7.5.1 Company profile
 - 7.5.2 Representative Chronic Idiopathic Constipation Drugs Product
 - 7.5.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
- 7.6 Merck
 - 7.6.1 Company profile
 - 7.6.2 Representative Chronic Idiopathic Constipation Drugs Product
 - 7.6.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Merck
- 7.7 Eli Lilly
 - 7.7.1 Company profile
 - 7.7.2 Representative Chronic Idiopathic Constipation Drugs Product
 - 7.7.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.8 Allergens
 - 7.8.1 Company profile
 - 7.8.2 Representative Chronic Idiopathic Constipation Drugs Product
 - 7.8.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Allergens
- 7.9 Chugai Pharmaceutical
 - 7.9.1 Company profile
 - 7.9.2 Representative Chronic Idiopathic Constipation Drugs Product
 - 7.9.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Chugai Pharmaceutical
- 7.10 Ferring International Center S.A.
 - 7.10.1 Company profile
 - 7.10.2 Representative Chronic Idiopathic Constipation Drugs Product
 - 7.10.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Ferring International Center S.A

7.11 Synergy Pharmaceuticals

7.11.1 Company profile

7.11.2 Representative Chronic Idiopathic Constipation Drugs Product

7.11.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals

7.12 Salix Pharmaceuticals Ltd

7.12.1 Company profile

7.12.2 Representative Chronic Idiopathic Constipation Drugs Product

7.12.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd

7.13 Sucampo Pharmaceuticals Inc

7.13.1 Company profile

7.13.2 Representative Chronic Idiopathic Constipation Drugs Product

7.13.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals Inc

7.14 Ironwood Pharmaceuticals Inc

7.14.1 Company profile

7.14.2 Representative Chronic Idiopathic Constipation Drugs Product

7.14.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals Inc

7.15 Valeant Pharmaceuticals International

7.15.1 Company profile

7.15.2 Representative Chronic Idiopathic Constipation Drugs Product

7.15.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International

7.16 Daiichi Sankyo

7.17 Cosmo Pharmaceuticals SA

7.18 Progenics Pharmaceuticals Inc

7.19 Theravance Biopharma Inc

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS

8.1 Industry Chain of Chronic Idiopathic Constipation Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS

- 9.1 Cost Structure Analysis of Chronic Idiopathic Constipation Drugs
- 9.2 Raw Materials Cost Analysis of Chronic Idiopathic Constipation Drugs
- 9.3 Labor Cost Analysis of Chronic Idiopathic Constipation Drugs
- 9.4 Manufacturing Expenses Analysis of Chronic Idiopathic Constipation Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Chronic Idiopathic Constipation Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/CA3C574A3B0MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA3C574A3B0MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970